News

Fierce Pharma2h
With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
BioSpace3d
Lilly’s Antibody Protects Patients From Losing Muscle While Taking Novo’s Wegovy
Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...
Eli Lilly to roll out diabetes medicine in prefilled pen
Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The ...
Fierce Pharma3h
After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Exclusive-New data show most US patients now stay on Wegovy, Zepbound after a year
By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...